Loading
AMEXHealthcareBiotechnology
Latest quote
$1.08
−$0.02 · -1.82%
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Previous close
$1.08
−$0.02 · -1.82%
Regular session · ET · Market data may be delayed.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Day range
Current $1.08
52-week range
Current $1.08
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
53
Mixed
Risk
61
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Day range
Current $1.08
52-week range
Current $1.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.56M USD | 9.5M USD | 8.95M USD | 14.7M USD | 3.9M USD |
| Cost of goods sold | 845K USD | 334K USD | 671K USD | 728K USD | 1.43M USD |
| Gross profit | 13.71M USD | 9.17M USD | 8.27M USD | 13.98M USD | 2.47M USD |
| Research and development | 17.73M USD | 12.47M USD | 15.71M USD | 13.99M USD | 33.91M USD |
| Selling, general, and administrative | 18.46M USD | 18.17M USD | 17.3M USD | 22.51M USD | 18.21M USD |
| Operating expenses | 35.49M USD | 30.64M USD | 33.01M USD | 36.5M USD | 51.68M USD |
| Interest income | 1.69M USD | 1.72M USD | 1.63M USD | 829K USD | 2K USD |
| Depreciation and amortization | 699K USD | 609K USD | 692K USD | 727K USD | 873K USD |
| Operating income | −21.78M USD | −21.48M USD | −24.73M USD | −22.52M USD | −49.21M USD |
| Net income | −63.53M USD | −18.61M USD | −21.49M USD | −26.27M USD | −43.02M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Dec 15, 2003 | $0.08Irregular | — | — |
Ex-dividend Dec 15, 2003
$0.08
Irregular
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.38M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM4.5M0.01%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF3.21M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO1.89M0.01%14.7B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB1.54M0.01%10.73B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO1.12M0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC693.59K0.05%1.49B USD0.60%$196.25+0.69%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC257.89K0.02%1.08B USD0.20%$90.38+0.33%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
